# Quantifying Hepatic Mitochondrial Fluxes in Humans

> **NCT05305287** · PHASE4 · RECRUITING · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 60 (estimated)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease
- Type 2 Diabetes
- Mitochondrial Metabolism Disorders

## Interventions

- **DRUG:** Pioglitazone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05305287
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05305287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05305287, "Quantifying Hepatic Mitochondrial Fluxes in Humans". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05305287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*